Dexcom bet on the high financial ceiling that exists by integrating its glucose monitoring capabilities into the ring, ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over ... relating to their glucose monitoring products, which estimate blood sugar levels.

Forget going to the doctor’s office; these companies are putting the power of tracking every aspect of your health into our ...

Adults in the US who want to measure their blood glucose levels ... The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription ...

Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding ...

Today, Benzinga 's options scanner spotted 11 uncommon options trades for DexCom. This isn't normal. The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish. Out ...

Abbott’s Lingo offers real-time glucose tracking to improve health and wellness. See my hands-on experience and if it’s worth ...

Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a ...

Bengaluru: Abbott Laboratories and DexCom said on Monday they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices. The agreement ...

DexCom (NASDAQ:DXCM – Get Free Report) was upgraded by stock analysts at Robert W. Baird from a “neutral” rating to an ...